Abstract:Objective To explore clinical features and the effect of treatment of neuromyelitis optica spectrum disorders (NMOSD) in childhood.Methods Children who were hospitalized in Department of Pediatrics,Peking University First Hospital from January 2013 to June 2018 and meeting diagnostic criteria of NMOSD proposed by the International Panel for NMOSD Diagnosis in 2015 were summarized and followed up.The basic information,symptoms of each attack,locations and patterns of new lesions,features of cerebrospinal fluid,serologic markers,treatments and outcomes in these patients were analyzed.Thirty-three children were included in the study,with 13 males and 20 females.The median age of onset was 6.83 (4.25,8.75) years.Compared aquaporin-4 immunoglobulin G (AQP4-IgG) associated NMOSD with myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) associated NMOSD.Mann-Whitney U test was used for continuous variables and Fisher test for categorical variables in comparison between AQP4-IgG and MOG-IgG associated NMOSD.Wilcoxon test was used for annualized relapse rate (ARR) before and after adding disease-modifying drugs.Results Optic neuritis (39％ (13/33) in initial attacks and 49％ (62/127) in total attacks) and myelitis (36％ (12/33) in initial attacks and 26％ (33/127) in total attacks) were the top two symptoms in both the initial attacks and all 127 attacks during follow-up.There was 42％ (37/89) of brain magnetic resonance imaging (MRI) scans in acute phase showing new lesions in supratentorial white matter,with 43％ (16/37) showing acute disseminated encepha lomyelitis (ADEM)-like or leukodystrophy-like patterns.AQP4-IgG was detected in 30％ (10/33) patients,and MOG-IgG was detected in 55％ (11/20) patients,with no combined positive case.In 20 patients treated with rituximab,two were treated after the initial attack.In the other 18 patients,the median annualized relapse rate decreased from 1.86 (1.52,2.60) before treatment to 0.28 (0,1.13) during treatment (Z=-3.376,P=0.001).Compared with AQP4-IgG associated NMOSD (10 cases),fever of unknown origin (8/40 vs.0/33,P=0.007) was more common,area postrema syndrome (0/40 vs.4/33,P=0.038) was fewer,cell count of cerebrospinal fluid (49.0 (17.5,115.0) ×106/L vs.5.5 (3.0,15.8)×106/L,Z=-3.526,P=0.000) was higher in MOG-IgG associated NMOSD (11 cases).Conclusions In childhood-onset NMOSD,optic neuritis and myelitis were top two symptoms.Childhood-onset NMOSD has high proportion of positive MOG-IgG.Lesions in supratentorial white matter are common.Rituximab could significantly decrease ARR of NMOSD in childhood.However,more studies should be conducted to explore the optimal treatment strategy in different antibody associated NMOSD.

Progress in preventive therapy of neuromyelitis optica spectrum disorder attack and pharmaceutical care for one pediatric patient

Effectiveness and Tolerability of Immunosuppressants and Monoclonal Antibodies in Preventive Treatment of Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Network Meta-Analysis.

Advances in Disease-Modifying Therapy of Neuromyelitis Optic Spectrum Disorders

Pharmaceutical care path design of neuromyelitis optica spectrum disorders

Efficacy and Safety of Azathioprine, Mycophenolate Mofetil, and Reduced Dose of Rituximab in Neuromyelitis Optica Spectrum Disorder

Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis

Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

Clinical Analysis of Neuromyelitis Optica Spectrum Disorders in Childhood

A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder

The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China

Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies

Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study

Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs)

Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders

Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials

Monoclonal Antibody Treatment for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder

Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options

Comparative Analysis of Treatment Outcomes in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab, Azathioprine, and Mycophenolate Mofetil: A Systematic Review and Meta-analysis.

High-efficacy therapies reduce clinical and radiological events more effectively than traditional treatments in neuromyelitis optica spectrum disorder